Insulin-dependent diabetes mellitus (IDDM) is mediated by a T lymphocyte- dependent autoimmune destruction of pancreatic b-cells. Although insulin therapy has increased the lifespan of type I diabetic patients, it has failed to influence the long-term complications of diabetes. The basis of these long-term complications is due to the failure of exogenous insulin therapy to achieve fine specificity of normal glucose homeostasis. The recent results of the DCCT that improved glycemic control reduces the progression of secondary complications of IDDM has provided impetus for the design of protocols to achieve euglycemia. In the recent past, much effort has been focused on identifying the autoantigens implicated in IDDM, with an ultimate goal of using them for immune intervention strategies to prevent IDDM during the preclinical stages. This method of study, although meritorious, does little to aid those patients already afflicted with established diabetes. For these patients, islet cell transplantation remains the most practical and most specific treatment to restore normoglycemia and thus, prevent the development of long-term complications of IDDM. A major drawback of the widespread application of islet transplantation for the treatment of diabetes has been the vulnerability of islet allografts to immunologic rejection. Recent advances in gene therapy provide hope for the molecular engineering of islets to promote donor- specific unresponsiveness. Both adenoviral and adenoassociated viral- mediated gene transfer offer the novel opportunity of transducing somatic, non-replicating cells with desirable genes. The overall objective of this project is to induce islet allograft tolerance. We propose to employ several well-characterized chemokines (i.e., uteroglobin, CTLA4Ig, vIL10, and TGFb1), utilizing the latest technologies of gene therapy to express these secretory immunomodulatory proteins within the islet cell allograft. These secretory cytokines have the capacity to immunomodulate the intraislet milieu and block several critical steps of the T cell activation cascade important in islet- directed alloimmune responses. Through the technique of islet-directed DNA virus-mediated gene therapy, we will introduce a """"""""multiple hit"""""""" concept of local immunomodulation to promote islet allograft tolerance.

Project Start
1999-07-15
Project End
2000-05-31
Budget Start
1998-10-01
Budget End
1999-09-30
Support Year
5
Fiscal Year
1999
Total Cost
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Sun, Zheng; Miller, Russell A; Patel, Rajesh T et al. (2012) Hepatic Hdac3 promotes gluconeogenesis by repressing lipid synthesis and sequestration. Nat Med 18:934-42
Zhao, G; Moore, D J; Lee, K M et al. (2010) An unexpected counter-regulatory role of IL-10 in B-lymphocyte-mediated transplantation tolerance. Am J Transplant 10:796-801
Yang, Jichun; Wang, Chunjiong; Li, Jing et al. (2009) PANDER binds to the liver cell membrane and inhibits insulin signaling in HepG2 cells. FEBS Lett 583:3009-15
Huang, Xiaolun; Moore, Daniel J; Mohiuddin, Mohammad et al. (2008) Inhibition of ICAM-1/LFA-1 interactions prevents B-cell-dependent anti-CD45RB-induced transplantation tolerance. Transplantation 85:675-80
Noorchashm, Hooman; Reed, Amy J; Rostami, Susan Y et al. (2006) B cell-mediated antigen presentation is required for the pathogenesis of acute cardiac allograft rejection. J Immunol 177:7715-22
Quinn 3rd, William J; Noorchashm, Negin; Crowley, Jenni E et al. (2006) Cutting edge: impaired transitional B cell production and selection in the nonobese diabetic mouse. J Immunol 176:7159-64
Yang, Jichun; Wong, Ryan K; Park, MieJung et al. (2006) Leucine regulation of glucokinase and ATP synthase sensitizes glucose-induced insulin secretion in pancreatic beta-cells. Diabetes 55:193-201
Burkhardt, Brant R; Greene, Scott R; White, Peter et al. (2006) PANDER-induced cell-death genetic networks in islets reveal central role for caspase-3 and cyclin-dependent kinase inhibitor 1A (p21). Gene 369:134-41
Burkhardt, Brant R; Yang, Michael C; Robert, Claudia E et al. (2005) Tissue-specific and glucose-responsive expression of the pancreatic derived factor (PANDER) promoter. Biochim Biophys Acta 1730:215-25
Yang, Jichun; Robert, Claudia E; Burkhardt, Brant R et al. (2005) Mechanisms of glucose-induced secretion of pancreatic-derived factor (PANDER or FAM3B) in pancreatic beta-cells. Diabetes 54:3217-28

Showing the most recent 10 out of 36 publications